Loading company…
TYK Medicines researches and develops antitumor drugs and drug development platforms.
Founded in 2018 and based in Shanghai, China, TYK Medicines develops tumor treatments, including TY-9591, TY-302, and TY-2136b, and operates small molecule and immunotherapy research platforms. In August 2024, it raised HKD 205.7 million in Pre-IPO funding and listed on the Hong Kong Exchange and Clearing Ltd.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in